Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Massachusetts
  • Boston


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD
    NCT04189562
    Condition:   Attention Deficit/Hyperactivity Disorder
    Intervention:   Other: SMS Intervention
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Indoor Air Quality and Respiratory Morbidity in School-Aged Children With BPD
    NCT04107701
    Conditions:   Bronchopulmonary Dysplasia;   Chronic Lung Disease of Newborn;   Environmental Exposure
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   National Institute of Environmental Health Sciences (NIEHS)
    Recruiting
  • Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders
    NCT03967743
    Conditions:   Genetic Disease;   Genetic Syndrome;   Genetic Predisposition to Disease;   Development, Infant;   Development, Child
    Intervention:  
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • The Use of Music for Neonates Post-Cardiac Surgery
    NCT03925584
    Condition:   Heart Defects, Congenital
    Intervention:   Other: Music Therapy
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth
    NCT03911414
    Conditions:   Mood Disturbance;   Mood Disorders;   Natural Supplements;   Alternative Treatment
    Interventions:   Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol;   Drug: Open-label Treatment with N-acetylcysteine
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Resiliency Training in Adolescents With NF1 and NF2
    NCT03873610
    Condition:   Neurofibromatoses
    Interventions:   Behavioral: Stress and Symptom Management Program 1;   Behavioral: Stress and Symptom Management Program 2
    Sponsors:   Massachusetts General Hospital;   United States Department of Defense
    Recruiting
  • Monitoring Of Scratch Via Accelerometry In Children
    NCT03873220
    Condition:   Atopic Dermatitis
    Interventions:   Device: Wrist Actigraphy Devices;   Device: Sleep Monitor;   Device: Polysomnography;   Device: Videography
    Sponsor:   Boston University
    Recruiting
  • Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
    NCT03757585
    Conditions:   Non-verbal Learning Disorder;   Autism Spectrum Disorder;   Autism
    Interventions:   Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol;   Drug: Open-label Treatment with N-acetylcysteine
    Sponsors:   Massachusetts General Hospital;   Demarest Lloyd Jr. Foundation
    Recruiting
  • CenteringParenting Clinical Intervention on Kindergarten Readiness in Early Childhood
    NCT03641092
    Conditions:   Parent-Child Relations;   Parenting;   Child Development;   Child Behavior
    Interventions:   Behavioral: CenteringParenting Intervention;   Behavioral: Routine Well Child Care
    Sponsors:   Boston Medical Center;   Centering Healthcare Institute;   Overdeck Family foundation;   Valhalla Charitable Foundation
    Recruiting
  • Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
    NCT03638453
    Condition:   Other Cancer
    Interventions:   Other: PediCARE;   Other: Usual Care
    Sponsors:   Dana-Farber Cancer Institute;   Charles H. Hood Foundation;   National Cancer Institute (NCI)
    Recruiting
  • Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
    NCT03532399
    Condition:   Drug Effect
    Intervention:   Drug: Bivalirudin
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Boston Outcomes of Autism in Toddlers Study
    NCT03517163
    Conditions:   Autism Spectrum Disorder;   Autism
    Intervention:  
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
    NCT03447782
    Condition:   New Daily Persistent Headache (NDPH)
    Intervention:   Drug: Naltrexone HCl (Bulk) Powder
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
    NCT03432065
    Conditions:   Autism Spectrum Disorder;   Anxiety
    Intervention:   Drug: Buspirone
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
    NCT03431064
    Conditions:   Anesthesia;   Intravenous Fluid;   Blood Pressure
    Interventions:   Other: Lung Recruitment Maneuver;   Other: Fluid Administration
    Sponsors:   Boston Children’s Hospital;   Masimo Corporation
    Recruiting
  • Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
    NCT03246243
    Condition:   Hypoxic-Ischemic Encephalopathy
    Interventions:   Device: nfant feeding solution;   Device: Waveguard (TM) EEG cap;   Device: BabyMEG
    Sponsors:   Boston Children’s Hospital;   Beth Israel Deaconess Medical Center;   Winchester Hospital
    Recruiting
  • Environmental Assessment of Sleep in Youth
    NCT03224455
    Conditions:   Sleep Disorders in Children;   Environmental Exposure
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital
    Recruiting
  • Innovative Approaches to Assessment of Pain Control and Sedation in the NICU
    NCT03057782
    Condition:   Pain, Postoperative
    Interventions:   Device: Waveguard (TM) EEG cap;   Device: Micro Movement Sensor;   Device: Pico Movement Sensor;   Device: QS Piezostimulator;   Device: tactileTM sensory evaluator
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric
    NCT03054831
    Condition:   Liquid Oxycodone
    Intervention:   Drug: liquid oxycodone
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Outcomes of an Intraoperative Bispectral Index Monitor
    NCT03052543
    Condition:   Anesthesia
    Intervention:   Device: BIS™ Complete 2--Channel Monitor
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices
    NCT02918435
    Conditions:   Basic Unmet Material Needs;   Patient Satisfaction;   Receipt of Community Resources;   Provider Referrals
    Intervention:   Behavioral: WE CARE
    Sponsors:   Boston Medical Center;   Pediatric Research in Office Settings;   Continuity Research Network;   Boston University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • The Evaluation of a Noninvasive Respiratory Monitor in Intubated Infants
    NCT02899351
    Condition:   Respiratory Complications
    Intervention:   Device: Respiratory Volume Monitor
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Blood Ropivacaine Concentrations Following Nerve Block in Infants and Toddlers Undergoing Esophageal Atresia Repair
    NCT02860091
    Condition:   Pain, Postoperative
    Intervention:   Drug: Ropivacaine infusion
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD
    NCT02708290
    Conditions:   Autistic Disorder;   Autism;   ASD
    Intervention:   Other: MITA imagination exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
    Sponsor:   ImagiRation, LLC
    Recruiting
  • Use of Amplification in Children With Unilateral Hearing Loss
    NCT02269124
    Condition:   Unilateral Hearing Loss
    Intervention:   Device: Hearing aid
    Sponsor:   Massachusetts Eye and Ear Infirmary
    Recruiting
  • Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
    NCT02044497
    Condition:   Pediatric Surgical Patient
    Intervention:   Drug: oral oxycodone
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Tau/P-Tau and Neurocognitive Outcomes in Children
    NCT03511729
    Conditions:   General Anesthetics Toxicity;   Postoperative Cognitive Dysfunction;   Child Development
    Intervention:  
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
    NCT01850355
    Conditions:   Autism Spectrum Disorders;   Anxiety
    Intervention:   Drug: Buspirone
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)
    NCT03015272
    Condition:   Autism
    Interventions:   Behavioral: Auditory-Motor Mapping Training;   Behavioral: Speech-Repetition Therapy
    Sponsors:   Beth Israel Deaconess Medical Center;   Boston University
    Recruiting
  • Kisspeptin in the Evaluation of Delayed Puberty
    NCT01438034
    Conditions:   Delayed Puberty;   Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   GnRH Deficiency
    Interventions:   Drug: kisspeptin 112-121;   Drug: GnRH
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder
    NCT00592267
    Condition:   Pediatric Bipolar Disorder
    Intervention:  
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • NIRS Monitoring in Premature Infants
    NCT02601339
    Conditions:   Hemorrhage;   Premature Infants;   Newborn;   Hydrocephalus
    Intervention:   Procedure: ETV/CPC
    Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease
    NCT04166526
    Condition:   Sickle Cell Disease
    Interventions:   Device: FDNIRS-DCS;   Device: MRI
    Sponsors:   Boston Children’s Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Optical Tissue Identification for Myocardial Architecture
    NCT04017975
    Conditions:   Ventricular Septal Defect;   Complete Atrioventricular Canal;   Tetralogy of Fallot With Pulmonary Stenosis
    Interventions:   Drug: Fluorescite;   Device: Cellvizio 100 Series System with Confocal Miniprobes
    Sponsors:   Aditya Kaza;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • VE416 for Treatment of Food Allergy
    NCT03936998
    Condition:   Peanut Allergy
    Interventions:   Combination Product: Vancomycin plus VE416 before PNOIT;   Combination Product: Vancomycin plus VE416 with PNOIT;   Combination Product: Placebo plus VE416 with PNOIT;   Combination Product: Placebo plus placebo with PNOIT
    Sponsors:   Massachusetts General Hospital;   Vedanta Biosciences, Inc.
    Recruiting
  • Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
    NCT03936465
    Conditions:   Solid Tumor, Childhood;   Lymphoma;   Brain Tumor, Pediatric
    Intervention:   Drug: BMS-986158
    Sponsors:   Dana-Farber Cancer Institute;   Stand Up To Cancer
    Recruiting
  • Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
    NCT03922451
    Condition:   Drug Effect
    Interventions:   Drug: piperacillin-tazobactam;   Drug: Cefazolin
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy
    NCT03857074
    Conditions:   Epilepsy;   Epilepsy Intractable
    Intervention:   Device: Green Light Exposure
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence
    NCT03786224
    Conditions:   Cannabis Use;   Adolescent Behavior
    Intervention:   Behavioral: Contingency Management
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
    NCT03768336
    Condition:   Cancer
    Interventions:   Other: Waitlist control;   Other: 3RP-AYA
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting
  • The Role of Estrogen in the Neurobiology of Eating Disorders
    NCT03740204
    Conditions:   Eating Disorders;   Hypoestrogenemia
    Interventions:   Drug: 17-β estradiol transdermal patches with cyclic progesterone;   Drug: Placebo patch and pill
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer
    NCT03709225
    Conditions:   Anxiety;   Oncology;   Stress
    Intervention:   Behavioral: Music-based meditation
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting
  • Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
    NCT03553875
    Conditions:   Autism;   Autism Spectrum Disorder;   Nonverbal Learning Disability
    Interventions:   Drug: Memantine Hydrochloride;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease
    NCT03462979
    Conditions:   Celiac Disease;   Gluten Sensitivity;   Gluten Enteropathy;   Gastrointestinal Disease;   Digestive System Disease;   Diet Modification;   Intestinal Disease;   Malabsorption Syndromes;   Patient Compliance;   Diagnostic Self Evaluation;   Quality of Life
    Intervention:   Device: Immunochromatographic lateral flow test
    Sponsors:   Boston Children’s Hospital;   Glutenostics, LLC
    Recruiting
  • Pilot Study of Metformin for Patients With Fanconi Anemia
    NCT03398824
    Condition:   Fanconi Anemia
    Intervention:   Drug: metformin HCl
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
    NCT03281889
    Condition:   Brain Tumor
    Intervention:   Radiation: Proton Beam
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting
  • Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness
    NCT03011151
    Conditions:   Gastroparesis;   Gastrointestinal Disorder, Functional;   Critical Illness
    Intervention:  
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy
    NCT02952222
    Condition:   Anesthesia
    Interventions:   Drug: Dexmedetomidine;   Drug: Propofol (Group P);   Drug: Propofol (Group DP)
    Sponsor:   Keira Mason
    Recruiting
  • Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
    NCT02845453
    Conditions:   Substance Use Disorders;   Bipolar Disorder;   Mood Disorders
    Interventions:   Drug: Quetiapine;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Validation of the Hospital Asthma Severity Score (HASS)
    NCT02782065
    Condition:   Asthma
    Intervention:   Other: Not an interventional study
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
    NCT02579044
    Condition:   Progeria
    Intervention:   Drug: Everolimus and lonafarnib
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Effects of Weight Loss Surgery on Bone Health in Adolescents
    NCT02557438
    Conditions:   Obesity;   Surgery
    Interventions:   Procedure: Roux-en-Y Gastric Bypass;   Procedure: Vertical Sleeve Gastrectomy
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
    NCT04134559
    Conditions:   Hepatocellular Carcinoma, Childhood;   Hepatocellular Carcinoma;   Liver Cancer;   Liver Cancer Pediatric
    Intervention:   Drug: Pembrolizumab
    Sponsor:   Allison O'Neill
    Recruiting
  • Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
    NCT03928288
    Condition:   Endometriosis
    Interventions:   Drug: Cabergoline 0.5 MG;   Drug: Placebo - Cap
    Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital
    Recruiting
  • Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)
    NCT03890679
    Condition:   Pediatric: Genetic Syndrome
    Intervention:   Diagnostic Test: rapid whole genomic sequencing (rWGS)
    Sponsors:   Tufts Medical Center;   Rady Children's Hospital, San Diego;   Children's Hospital Medical Center, Cincinnati;   MOUNT SINAI HOSPITAL;   N.C. Children's Hospital;   University of Pittsburgh
    Recruiting
  • Phase II Study of Proton Radiation Therapy for Neuroblastoma
    NCT02112617
    Conditions:   Neuroblastoma;   Ganglioneuroblastoma
    Intervention:   Radiation: Proton Beam Radiation Therapy
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting
  • JASPER Early Intervention for Tuberous Sclerosis
    NCT03422367
    Condition:   Tuberous Sclerosis
    Intervention:   Behavioral: JASPER
    Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Boston Children’s Hospital;   Massachusetts General Hospital
    Recruiting
  • High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade
    NCT03162432
    Conditions:   IBD;   Ulcerative Colitis;   Crohn Disease
    Intervention:   Drug: Vitamin D3
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Early Peanut Introduction: Translation to Clinical Practice
    NCT03019328
    Condition:   Peanut Allergy
    Intervention:   Other: Peanut in diet
    Sponsors:   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID);   Massachusetts General Hospital
    Recruiting
  • Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
    NCT02355340
    Conditions:   Bone Mineral Density;   Childhood Cancer Survivors
    Interventions:   Other: Dual energy x-ray absorptiometry (DXA);   Other: Peripheral quantitative computed tomography (pQCT)
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting
  • Bronchopulmonary Disease (BPD) Patient Registry
    NCT00951366
    Condition:   Bronchopulmonary Disease
    Intervention:   Other: Patient Registry
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Palbociclib + Ganitumab In Ewing Sarcoma
    NCT04129151
    Conditions:   Ewing Sarcoma;   Ewing's Sarcoma Recurrent
    Interventions:   Drug: Palbociclib;   Drug: Ganitumab
    Sponsors:   Dana-Farber Cancer Institute;   1 Million 4 Anna Foundation;   Carson Sarcoma Foundation;   Teaming up to Fight Childhood Cancer;   ChemoWarrior: the eli sidler foundation;   i-ROK Foundation;   Rutledge Cancer Foundation;   Alan B. Slifka Foundation
    Recruiting
  • LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
    NCT03750513
    Conditions:   Anaplastic Ependymoma;   Ependymoma
    Interventions:   Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Patient and Parent Preferences for an On-Body Automated Insulin Delivery System
    NCT03534544
    Condition:   Diabetes Mellitus, Type 1
    Intervention:  
    Sponsors:   Joslin Diabetes Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
    NCT02153957
    Condition:   Brain Tumor
    Intervention:   Behavioral: Physical Activity
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
    NCT03996967
    Conditions:   Pneumonia, Bacterial;   Viral Infection;   Clinical Pneumonia;   Plasmodium Falciparum Malaria;   Malaria;   Infections, Respiratory
    Intervention:  
    Sponsors:   Boston University;   National Institute of Allergy and Infectious Diseases (NIAID);   Medical Research Council Unit, The Gambia, LSTMH;   Laboratory of Transnational Immunology, UMC Utrecht
    Recruiting
  • Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
    NCT03837496
    Conditions:   Breast Cancer;   Adherence, Medication
    Interventions:   Other: STRIDE;   Other: Medication Monitoring Control
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting
  • Clinical Trial to Improve the Magnetic Levator Prosthesis
    NCT03818204
    Conditions:   Blepharoptosis;   Ptosis, Eyelid;   Myasthenia Gravis;   Stroke;   Traumatic Brain Injury
    Intervention:   Device: Magnetic Levator Prosthesis (MLP)
    Sponsor:   Massachusetts Eye and Ear Infirmary
    Recruiting
  • Calcitriol Monotherapy for X-Linked Hypophosphatemia
    NCT03748966
    Conditions:   X-linked Hypophosphatemia;   Hypophosphatemic Rickets;   Hypophosphatemic Rickets, X-Linked Dominant
    Intervention:   Drug: Calcitriol
    Sponsors:   Massachusetts General Hospital;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting
  • Pediatric Gastroparesis Registry
    NCT03680820
    Conditions:   Gastroparesis;   Gastroparesis-like Syndrome
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Scheduled Ketorolac Administration After Cesarean Section and Its Effect on Opioid Consumption: a Randomized Control Trial
    NCT03678675
    Conditions:   Post-operative Pain;   Post-partum Pain;   Cesarean Section Complications
    Intervention:   Drug: Ketorolac
    Sponsor:   Tufts Medical Center
    Recruiting
  • Seizure Rescue Medication: Caregiver Education in a Simulation Setting
    NCT03562351
    Condition:   Status Epilepticus
    Interventions:   Other: Verbal Instructions Educational Intervention;   Other: Video Educational Intervention;   Other: Mannequin Educational Intervention
    Sponsor:   Boston Children’s Hospital
    Recruiting
  • Genetics of Ehlers-Danlos Syndrome
    NCT03093493
    Conditions:   Genetics Syndrome;   Ehlers-Danlos Syndrome
    Intervention:   Diagnostic Test: Genotyping
    Sponsor:   Boston University
    Recruiting
  • Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies
    NCT03059420
    Conditions:   Congenital Fibrosis of Extraocular Muscles;   Duane Retraction Syndrome;   Duane Radial Ray Syndrome;   Mobius Syndrome;   Brown Syndrome;   Marcus Gunn Syndrome;   Strabismus Congenital;   Horizontal Gaze Palsy;   Horizontal Gaze Palsy With Progressive Scoliosis;   Facial Palsy;   Facial Paresis, Hereditary, Congenital;   Third Nerve Palsy;   Fourth Nerve Palsy;   Sixth Nerve Palsy;   Synkinesis;   Ocular Motility Disorders;   Levator-Medial Rectus Synkinesis;   Athabaskan Brainstem Dysgenesis;   Tongue Paralysis;   Ninth Nerve Disorder;   Fifth Nerve Palsy;   Seventh Nerve Palsy;   Eleventh Nerve Disorder;   Twelfth Nerve Disorder;   Vagus Nerve Paralysis;   Moebius Sequence
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   Howard Hughes Medical Institute;   National Eye Institute (NEI)
    Recruiting
  • Low Dose Naltrexone for Chronic Pain From Arthritis
    NCT03008590
    Conditions:   Osteoarthritis;   Arthritis, Rheumatoid;   Arthritis, Psoriatic
    Interventions:   Drug: Naltrexone;   Drug: Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Hereditary Risk Factors for Thyroid Cancer
    NCT02747888
    Condition:   Thyroid Cancer
    Intervention:   Genetic: •Referral to Genetic Counselor, if indicated
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting
  • Identification of L3-L4 Interspace in Parturients
    NCT02697747
    Condition:   Healthy
    Intervention:   Other: Education
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting
  • Novel Interventions for GWVI
    NCT02661997
    Condition:   Gulf War Veteran's Illness
    Interventions:   Behavioral: Tai Chi Intervention;   Behavioral: Wellness Intervention
    Sponsors:   VA Office of Research and Development;   Boston University;   Tufts Medical Center
    Recruiting
  • Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
    NCT02610439
    Conditions:   Breast Carcinoma;   Neuropathy
    Intervention:   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
    NCT02610426
    Condition:   Breast Carcinoma
    Intervention:   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
    NCT02610413
    Condition:   Breast Carcinoma
    Intervention:   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
    NCT02555969
    Conditions:   Amyloidosis;   Primary Amyloidosis
    Intervention:  
    Sponsor:   Tufts Medical Center
    Recruiting
  • Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
    NCT00592592
    Condition:   Rhabdomyosarcoma
    Intervention:   Radiation: Proton Beam Radiation
    Sponsors:   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   Brigham and Women's Hospital;   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting
  • Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
    NCT02202681
    Conditions:   Celiac Disease;   Healthy
    Intervention:   Device: OFDI Capsule
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients
    NCT02193542
    Condition:   Indication for Care or Intervention Related to Labor or Delivery With Baby Delivered
    Intervention:  
    Sponsor:   Brigham and Women's Hospital
    Recruiting
  • A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
    NCT03857841
    Condition:   Bronchopulmonary Dysplasia
    Interventions:   Biological: UNEX-42;   Biological: Phosphate-buffered saline
    Sponsor:   United Therapeutics
    Recruiting
  • Non-Anesthetized Plexus Technique for Infant (BPBP) MRI Evaluation
    NCT03560999
    Conditions:   Brachial Plexus Palsy Due to Birth Trauma;   Injury;   Newborn
    Intervention:  
    Sponsor:   Shriners Hospitals for Children
    Recruiting
  • TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders
    NCT02836405
    Conditions:   Autism Spectrum Disorder;   Intellectual Disability
    Intervention:   Device: Transcranial Magnetic Stimulation
    Sponsors:   Boston Children’s Hospital;   Beth Israel Deaconess Medical Center;   National Institute of Mental Health (NIMH)
    Recruiting
  • Identification of Genetic Causes of Bicuspid Aortic Valve Disease
    NCT01026571
    Condition:   Bicuspid Aortic Valve
    Intervention:  
    Sponsors:   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Brigham and Women's Hospital
    Recruiting
  • Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
    NCT00494169
    Conditions:   Hypogonadotropic Hypogonadism;   Kallmann Syndrome;   Puberty, Delayed;   Puberty, Precocious;   GnRH Deficiency
    Intervention:  
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
    NCT00392756
    Conditions:   Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   GnRH Deficiency
    Intervention:   Drug: gonadotropin releasing hormone (GnRH)
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Molecular and Genetic Studies of Congenital Myopathies
    NCT00272883
    Conditions:   Central Core Disease;   Centronuclear Myopathy;   Congenital Fiber Type Disproportion;   Multiminicore Disease;   Myotubular Myopathy;   Nemaline Myopathy;   Rigid Spine Muscular Dystrophy;   Undefined Congenital Myopathy
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   Muscular Dystrophy Association
    Recruiting
  • Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
    NCT03349242
    Condition:   Retinitis Pigmentosa
    Intervention:  
    Sponsor:   MeiraGTx UK II Ltd
    Recruiting
  • Aerobic Exercise for Concussion
    NCT02959216
    Conditions:   Mild Traumatic Brain Injury;   Acute Brain Injury;   Brain Concussion
    Interventions:   Other: Aerobic Exercise;   Other: Stretching Exercise
    Sponsors:   Children's Hospital of Philadelphia;   University at Buffalo;   Boston Children’s Hospital
    Recruiting
  • A Randomized Controlled Trial of Leg Length Discrepancy Techniques
    NCT02260856
    Condition:   Leg Length Discrepancy
    Interventions:   Device: Tantalum Beads & Injector;   Procedure: Percutaneous Drill Epiphysiodesis;   Procedure: Percutaneous Screw Epiphysiodesis
    Sponsors:   Hospital for Special Surgery, New York;   Boston Children’s Hospital;   The Hospital for Sick Children
    Recruiting
  • Fimepinostat in Treating Brain Tumors in Children and Young Adults
    NCT03893487
    Conditions:   Diffuse Intrinsic Pontine Glioma;   Recurrent Anaplastic Astrocytoma;   Recurrent Glioblastoma;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma
    Interventions:   Drug: Fimepinostat;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Sabine Mueller, MD, PhD;   Pacific Pediatric Neuro-Oncology Consortium;   Cannonball Kids' Cancer Foundation;   Curis, Inc.
    Recruiting
  • Positive Steps to Enhance Problem Solving Skills
    NCT03092531
    Condition:   Adherence
    Intervention:   Behavioral: Positive STEPS
    Sponsor:   Brown University
    Recruiting
  • PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
    NCT03139331
    Condition:   Sarcoma
    Interventions:   Drug: Pazopanib;   Drug: Irinotecan;   Drug: Temozolomide
    Sponsors:   University of California, San Francisco;   UCSF Benioff Children’s Hospital Oakland;   Dana-Farber Cancer Institute;   Alex's Lemonade Stand Foundation
    Recruiting
  • Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
    NCT03728426
    Condition:   Cytomegalovirus Infections
    Intervention:   Drug: Letermovir
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting
  • M6620 (VX-970) in Selected Solid Tumors
    NCT03718091
    Conditions:   Solid Tumor;   Leiomyosarcoma;   Osteosarcoma
    Intervention:   Drug: M6620
    Sponsors:   Massachusetts General Hospital;   EMD Serono
    Recruiting
  • Natural History Study of Patients With Canavan Disease, CAN Inform
    NCT04126005
    Condition:   Canavan Disease
    Intervention:  
    Sponsor:   Aspa Therapeutics
    Recruiting
  • Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)
    NCT03252847
    Condition:   X-Linked Retinitis Pigmentosa
    Intervention:   Genetic: AAV-RPGR
    Sponsors:   MeiraGTx UK II Ltd;   Syne Qua Non Limited;   Bionical-Emas Pharma Ltd
    Recruiting
  • Non-blinded Data Collection Study of Concussion Using the BrainPulse(TM)
    NCT02812225
    Conditions:   Brain Concussion;   Mild Traumatic Brain Injury
    Intervention:   Device: BrainPulse
    Sponsor:   Jan Medical, Inc.
    Recruiting
  • A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
    NCT01804166
    Condition:   Hepatosplenic T-Cell Lymphoma
    Interventions:   Drug: Infliximab;   Drug: Golimumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
    NCT03654716
    Conditions:   Leukemia;   Brain Tumor;   Solid Tumor;   Lymphoma
    Interventions:   Drug: ALRN-6924;   Drug: Cytarabine
    Sponsors:   Dana-Farber Cancer Institute;   TeamConnor Childhood Cancer Foundation;   Cookies for Kids' Cancer;   Aileron Therapeutics
    Recruiting
  • Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial
    NCT03045276
    Conditions:   Spina Bifida;   Kidney Transplant
    Interventions:   Behavioral: Behavioral Feedback and Economic Incentives: Arm 1;   Behavioral: Behavioral Feedback and Economic Incentives: Arm 2
    Sponsors:   Children's Hospital of Philadelphia;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Boston Children’s Hospital;   Children's Healthcare of Atlanta;   Children's Mercy Hospital Kansas City;   Ann & Robert H Lurie Children's Hospital of Chicago;   Seattle Children's Hospital
    Recruiting
  • Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
    NCT02909777
    Conditions:   Lymphoma;   Neuroblastoma;   Brain Tumor;   Solid Tumor
    Intervention:   Drug: CUDC-907
    Sponsors:   Dana-Farber Cancer Institute;   Curis, Inc.
    Recruiting
  • Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
    NCT04181723
    Condition:   Rett Syndrome
    Interventions:   Drug: Trofinetide;   Other: Placebo
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)
    NCT03910075
    Conditions:   Perinatal Stroke;   Hemiparesis
    Interventions:   Behavioral: I-ACQUIRE - High Dosage;   Behavioral: I-ACQUIRE - Moderate Dosage;   Behavioral: Usual & Customary Treatment (U&CT)
    Sponsors:   Virginia Polytechnic Institute and State University;   Ohio State University;   Nationwide Children's Hospital;   Stanford University;   University of Cincinnati;   Medical University of South Carolina
    Recruiting
  • iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children
    NCT03815019
    Conditions:   Feeding Behavior;   Feeding Disorder of Infancy or Early Childhood
    Interventions:   Drug: Megestrol Acetate;   Behavioral: iKanEat Behavioral Intervention
    Sponsor:   University of Kansas Medical Center
    Recruiting
  • Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
    NCT03831880
    Condition:   Growth Hormone Deficiency
    Interventions:   Drug: Genotropin;   Drug: somatrogon
    Sponsor:   Pfizer
    Recruiting
  • Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
    NCT01858168
    Conditions:   Ewing Sarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Olaparib;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Single Ascending Dose Study in Participants With LCA10
    NCT03872479
    Conditions:   Blindness;   Leber Congenital Amaurosis 10;   Vision Disorders;   Eye Diseases;   Eye Diseases, Hereditary;   Eye Disorders Congenital;   Retinal Disease;   Retinal Degeneration
    Intervention:   Drug: AGN-151587
    Sponsors:   Allergan;   Editas Medicine, Inc.
    Recruiting
  • Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
    NCT03364231
    Condition:   Waldenstrom Macroglobulinemia
    Intervention:   Drug: Umbralisib
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • Low-Dose Atropine for Treatment of Myopia
    NCT03334253
    Condition:   Myopia
    Interventions:   Drug: Atropine;   Other: Placebo Eyedrops
    Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
    Recruiting
  • Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
    NCT02437851
    Conditions:   Anal Squamous Cell Carcinoma;   HIV Infection;   Stage 0 Anal Canal Cancer;   Stage I Anal Canal Cancer
    Intervention:   Procedure: Therapeutic Conventional Surgery
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   AIDS and Cancer Specimen Resource;   University of Arkansas
    Recruiting
  • Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
    NCT03138655
    Conditions:   Ulcerative Colitis;   Crohn's Disease
    Intervention:   Drug: Vedolizumab
    Sponsor:   Takeda
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
    NCT03531814
    Conditions:   Neurofibromatosis 1;   Neurofibroma, Plexiform
    Intervention:   Behavioral: Medication Event Monitoring System (MEMS)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • OT-58 as an Enzyme Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)
    NCT03406611
    Condition:   Homocystinuria
    Interventions:   Drug: OT-58;   Drug: Placebo
    Sponsor:   Orphan Technologies Ltd
    Recruiting
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
    NCT01302847
    Condition:   HIV Infections
    Interventions:   Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • TechStep: Technology-based Stepped Care to Stem Transgender Adolescent Risk Transmission
    NCT04000724
    Condition:   HIV
    Interventions:   Behavioral: Text Messaging (Text+Step);   Behavioral: WebApp (App+Step);   Behavioral: Information/No Step
    Sponsors:   Friends Research Institute, Inc.;   San Diego State University;   University of North Carolina;   Emory University;   Texas Children's Hospital;   Children's Hospital of Philadelphia;   The Fenway Institute;   Hunter College of City University of New York;   Children's Hospital Los Angeles
    Recruiting
  • A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
    NCT03633058
    Condition:   Rett Syndrome
    Intervention:   Drug: Ketamine
    Sponsors:   Rett Syndrome Research Trust;   Vanderbilt University Medical Center
    Recruiting
  • Kids FACE FEARS Comparative Effectiveness Research
    NCT03707158
    Conditions:   Child Anxiety;   Anxiety Disorder of Adolescence
    Interventions:   Behavioral: Office-based Cognitive-Behavioral Therapy;   Behavioral: Digital Cognitive-Behavioral Therapy
    Sponsors:   Boston Medical Center;   Patient-Centered Outcomes Research Institute;   Massachusetts General Hospital;   South Boston Community Health Center;   Johns Hopkins University;   Dundalk Pediatric Associates;   Harborview Injury Prevention and Research Center;   Seattle Children's Hospital;   Swedish Medical Center;   Nicklaus Children's Hospital f/k/a Miami Children's Hospital;   Boston University;   Florida International University;   University of Washington
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Drug: Melphalan;   Drug: Melphalan Hydrochloride;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • STRIDE Biorepository
    NCT02843347
    Condition:   Anemia, Sickle Cell
    Intervention:   Procedure: Blood draw
    Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
    NCT02766465
    Condition:   Sickle Cell Disease
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Hematopoietic Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program;   Emory University
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Participants With 15Q Duplication Syndrome or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
    NCT03694275
    Conditions:   15q Duplication Syndrome;   CDKL5 Deficiency Disease
    Intervention:   Drug: TAK-935
    Sponsors:   Takeda;   Ovid Therapeutics Inc.
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
    NCT03581292
    Conditions:   Anaplastic Astrocytoma;   Glioblastoma;   Malignant Glioma
    Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
    NCT03526250
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
    NCT03245840
    Condition:   Eosinophilic Esophagitis (EoE)
    Intervention:   Drug: Budesonide oral suspension
    Sponsor:   Shire
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
    NCT03057626
    Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
    NCT02772965
    Condition:   Pediatric Crohn's Disease
    Interventions:   Drug: Methotrexate;   Other: Sugar pill (placebo)
    Sponsors:   University of North Carolina, Chapel Hill;   Patient-Centered Outcomes Research Institute;   ImproveCareNow (ICN);   The Leona M. and Harry B. Helmsley Charitable Trust;   Children's Hospital Medical Center, Cincinnati;   Grifols Diagnostics Solutions, Inc;   National Institutes of Health (NIH);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting
  • A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    NCT02601937
    Conditions:   Rhabdoid Tumors;   INI1-negative Tumors;   Synovial Sarcoma;   Malignant Rhabdoid Tumor of Ovary
    Intervention:   Drug: Tazemetostat
    Sponsor:   Epizyme, Inc.
    Recruiting
  • LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
    NCT02205762
    Condition:   Langerhans Cell Histiocytosis
    Interventions:   Drug: Prednisone;   Drug: Vinblastine;   Drug: mercaptopurine;   Drug: INDOMETHACIN;   Drug: Methotrexate;   Drug: Cytosine Arabinoside;   Drug: 2-chlorodeoxyadenosine;   Procedure: hematopoietic stem cell transplantation (RIC-HSCT);   Biological: Intravenous immunoglobulin
    Sponsors:   North American Consortium for Histiocytosis;   Histiocyte Society
    Recruiting
  • Pediatric Adenotonsillectomy Trial for Snoring
    NCT02562040
    Condition:   Sleep-Disordered Breathing
    Interventions:   Procedure: Early Adenotonsillectomy (eAT);   Behavioral: Watchful Waiting with Supportive Care (WWSC)
    Sponsors:   Brigham and Women's Hospital;   Children's Hospital of Philadelphia;   University Hospitals Cleveland Medical Center;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   University of Texas Southwestern Medical Center;   University of Rochester;   Children's Hospital of The King's Daughters;   Boston Children’s Hospital
    Recruiting
  • Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
    NCT02562235
    Condition:   Hypertension, Pulmonary
    Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
    Sponsors:   Bayer;   Merck Sharp & Dohme Corp.
    Recruiting
  • A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
    NCT04102189
    Conditions:   Overweight;   Obesity
    Interventions:   Drug: Semaglutide;   Drug: Placebo
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
    NCT03725007
    Condition:   Juvenile Idiopathic Arthritis (JIA)
    Intervention:   Drug: Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • Developing e-Health Systems to Improve Growth and Nutrition in CF
    NCT03635762
    Condition:   Cystic Fibrosis in Children
    Intervention:   Behavioral: Be In Charge
    Sponsors:   Boston Children’s Hospital;   Cystic Fibrosis Foundation;   Johns Hopkins University;   Children's Hospital Medical Center, Cincinnati
    Recruiting
  • Flourish™ Pediatric Esophageal Atresia
    NCT03615495
    Conditions:   Esophageal Atresia;   Digestive System Abnormalities;   Esophageal Disorders Congenital
    Intervention:   Device: Flourish Pediatric Esphogeal Atresia device
    Sponsor:   Cook Research Incorporated
    Recruiting
  • Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
    NCT00550992
    Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: prednisolone;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Dutch Childhood Oncology Group;   BFM Germany;   CORS Monza Italy;   Associazione Italiana Ematologia Oncologia Pediatrica;   Australian and New Zealand Children's Oncology Group;   BFM Austria;   CLCG France Belgium Portugal;   COALL Germany;   CPH, Czech republic;   DFCI consortium USA;   FRALLE France;   Hong Kong;   MD Anderson USA;   NOPHO Scandinavian countries;   PINDA, Chile;   PPLLSG Poland;   Seattle USA;   SJCRH USA;   UKCCSG United Kingdom
    Recruiting
  • CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
    NCT03924219
    Conditions:   Heart Transplant Infection;   Kidney Transplant Infection;   Liver Transplant Infection;   CMV
    Intervention:   Other: CMV T cell Immunity Assay
    Sponsors:   Vanderbilt University Medical Center;   ViraCor Laboratories
    Recruiting
  • A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
    NCT03875534
    Condition:   Achondroplasia
    Intervention:  
    Sponsor:   Ascendis Pharma A/S
    Recruiting
  • A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
    NCT03755713
    Condition:   Peanut Allergy
    Interventions:   Drug: ASP0892;   Drug: Placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Safety and PK Study of IV Eravacycline
    NCT03696550
    Condition:   Bacterial Infections
    Intervention:   Drug: Eravacycline (TP-434)
    Sponsor:   Tetraphase Pharmaceuticals, Inc.
    Recruiting
  • Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
    NCT03691779
    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-445;   Drug: TEZ;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
    NCT02204904
    Conditions:   X-Linked Adrenoleukodystrophy (X-ALD);   Cerebral Adrenoleukodystrophy (CALD);   Adrenoleukodystrophy (ALD)
    Intervention:   Genetic: Allo-HSCT
    Sponsor:   bluebird bio
    Recruiting
  • Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
    NCT03332095
    Condition:   HIV Infections
    Interventions:   Drug: Doravirine (DOR);   Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF);   Drug: Antiretroviral (ARV) medications
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
    NCT03292588
    Condition:   Asthma
    Interventions:   Biological: Mepolizumab;   Drug: Placebo
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium;   GlaxoSmithKline
    Recruiting
  • Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
    NCT03113760
    Conditions:   NLRC4-MAS;   XIAP Deficiency
    Interventions:   Drug: Tadekinig alfa;   Other: 0.9% sodium chloride
    Sponsor:   AB2 Bio Ltd.
    Recruiting
  • AVATAR Anesthesia Alternative in Pediatric Radiotherapy: A Multi-Center Study
    NCT03991156
    Condition:   Anesthesia
    Interventions:   Device: Audio-Visual Assisted Therapeutic Ambience in Radiotherapy;   Other: Quality of Life Survey, PedsQL3.0;   Other: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)
    Sponsor:   Stanford University
    Recruiting
  • Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
    NCT03940586
    Condition:   Cytomegalovirus (CMV) Infection
    Interventions:   Drug: Letermovir oral granules;   Drug: Letermovir tablet;   Drug: Letermovir intravenous
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Pediatric ACL: Understanding Treatment Options
    NCT02772770
    Condition:   Anterior Cruciate Ligament Reconstruction
    Interventions:   Other: Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions;   Procedure: Surgical technique: Transphyseal reconstruction;   Procedure: Surgical technique: Partial transphyseal reconstruction;   Procedure: Surgical technique: Physeal sparing reconstruction by the Anderson method;   Procedure: Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method
    Sponsors:   Boston Children’s Hospital;   Children's Hospital of Philadelphia;   Children's Hospital Medical Center, Cincinnati;   Rady Children's Hospital, San Diego;   Washington University School of Medicine;   Children's Healthcare of Atlanta;   The Cleveland Clinic;   Tennessee Orthopedic Alliance;   Hospital for Special Surgery, New York;   Stanford University
    Recruiting
  • Cockroach Immunotherapy in Children and Adolescents
    NCT03541187
    Condition:   Persistent Asthma
    Interventions:   Biological: German cockroach allergenic extract;   Biological: Placebo for German cockroach allergenic extract
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium
    Recruiting
  • A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
    NCT02332668
    Conditions:   Melanoma;   Lymphoma;   Solid Tumor;   Classical Hodgkin Lymphoma;   Microsatellite-instability-high Solid Tumor
    Intervention:   Biological: Pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
    NCT03217136
    Condition:   Complicated Intra-Abdominal Infection
    Interventions:   Drug: Ceftolozane;   Drug: Tazobactam;   Drug: Metronidazole;   Drug: Meropenem;   Drug: Placebo for Metronidazole
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
    NCT02124772
    Condition:   Cancer
    Interventions:   Drug: Trametinib;   Drug: Dabrafenib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Dyslipidemia of Obesity Intervention in Teens
    NCT02956590
    Conditions:   Dyslipidemia;   Obesity
    Interventions:   Drug: Pitavastatin;   Drug: Placebo
    Sponsors:   New England Research Institutes;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
    NCT04110145
    Condition:   Functional Constipation
    Interventions:   Drug: Linaclotide;   Drug: Placebo
    Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • Linaclotide Safety and Efficacy, Functional Constipation, in Pediatric Participants 6 to 17 Years of Age
    NCT04026113
    Condition:   Functional Constipation
    Interventions:   Drug: Linaclotide 72 μg;   Drug: Placebo
    Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
    NCT04007991
    Condition:   Tourette Syndrome in Children; Tourette Syndrome in Adolescents
    Intervention:   Drug: Ecopipam
    Sponsor:   Emalex Biosciences Inc.
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants
    NCT03979313
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Placebo
    Sponsor:   MedImmune LLC
    Recruiting
  • A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
    NCT03959488
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Palivizumab
    Sponsor:   MedImmune LLC
    Recruiting
  • The Safety and Efficacy of SYD-101 in Children With Myopia
    NCT03918915
    Conditions:   Nearsightedness;   Near Sightedness;   Near-sightedness
    Interventions:   Drug: SYD-101 Dose 1;   Drug: SYD-101 Dose 2;   Drug: Vehicle
    Sponsor:   Sydnexis, Inc.
    Recruiting
  • Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
    NCT03916185
    Condition:   Respiratory Syncytial Virus (RSV)
    Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L Vaccine;   Biological: RSV 6120/ΔNS2/1030s Vaccine;   Biological: RSV 276 Vaccine;   Biological: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
    NCT03740919
    Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: LY900014;   Drug: Insulin Lispro
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
    NCT03695237
    Condition:   Central Precocious Puberty (CPP)
    Intervention:   Drug: Leuprolide Acetate (LA)
    Sponsor:   AbbVie
    Recruiting
  • Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
    NCT03682770
    Condition:   Peanut Allergy
    Interventions:   Drug: Dupilumab;   Drug: Placebo matching dupilumab;   Drug: AR101
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi;   Aimmune Therapeutics, Inc.
    Recruiting
  • Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
    NCT03672422
    Conditions:   Pancreatitis, Chronic;   Pancreatitis, Acute
    Interventions:   Diagnostic Test: Blood sample;   Behavioral: Patient questionnaires;   Diagnostic Test: Saliva sample;   Diagnostic Test: Urine sample
    Sponsors:   Aliye Uc;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
    NCT03656510
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: JNJ-53718678;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
    NCT03601637
    Condition:   Cystic Fibrosis
    Interventions:   Drug: LUM;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03596645
    Condition:   Colitis, Ulcerative
    Interventions:   Drug: Golimumab;   Drug: Infliximab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents
    NCT03497676
    Condition:   HIV Infections
    Interventions:   Drug: Oral Cabotegravir (CAB);   Drug: Oral Rilpivirine (RPV);   Drug: Long-Acting Injectable Cabotegravir (CAB LA);   Drug: Long-Acting Injectable Rilpivirine (RPV LA);   Drug: Combination Antiretroviral Therapy (cART)
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   ViiV
    Recruiting
  • Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
    NCT03474965
    Condition:   Sickle Cell Disease
    Intervention:   Drug: Crizanlizumab
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Developmental Impact of NICU Exposures (DINE)
    NCT03061890
    Condition:   Prematurity
    Intervention:  
    Sponsors:   Albert Einstein College of Medicine;   National Institutes of Health (NIH)
    Recruiting
  • An Efficacy and Safety Study of Palovarotene for the Treatment of MO
    NCT03442985
    Condition:   Exostoses, Multiple Hereditary
    Interventions:   Drug: Palovarotene 2.5 mg;   Drug: Palovarotene 5.0 mg;   Other: Placebo
    Sponsor:   Clementia Pharmaceuticals Inc.
    Recruiting
  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
    NCT03429543
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
    NCT03346434
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: Dupilumab;   Drug: Matching placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
    NCT02849457
    Condition:   Tuberous Sclerosis Complex
    Interventions:   Drug: Vigabatrin;   Drug: Placebo
    Sponsors:   Martina Bebin;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
    NCT03227029
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L;   Biological: RSV 276;   Biological: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission
    NCT03223753
    Condition:   Acute Lymphoblastic Leukemia in Remission
    Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
    NCT03211247
    Condition:   Peanut Allergy
    Interventions:   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Placebo
    Sponsor:   DBV Technologies
    Recruiting
  • Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
    NCT03196427
    Conditions:   Ulcerative Colitis;   Crohn's Disease
    Intervention:   Drug: Vedolizumab
    Sponsor:   Takeda
    Recruiting
  • Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
    NCT03182907
    Condition:   Clostridium Difficile Infection
    Interventions:   Biological: Bezlotoxumab;   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
    NCT03170518
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
    NCT03107871
    Conditions:   Cmv Congenital;   CMV;   Congenital Cmv;   SNHL;   Sensorineural Hearing Loss
    Interventions:   Drug: Valganciclovir;   Drug: Simple Syrup
    Sponsors:   Albert Park;   National Institute on Deafness and Other Communication Disorders (NIDCD);   Genentech, Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC